ERBB2 and neoplasm: HER2-positive tumors can show heterogeneous HER2 expression and heterogeneous behavior, whatever due to clonal selection or EMT, for this reason additional driver mutations should be investigated and taken into account for targeted therapies able to hamper tumor progression.